Why is Replimune stock surging today?
Replimune stock experienced a significant surge of 15.3% in mid-day trading today, reaching a price of $13.90 and hitting a new 52-week high of $13.99. This surge was triggered by a combination of factors, including the company's fourth quarter earnings release, a recent FDA approval, and a newly priced equity offering. The FDA granted accelerated approval to Replimune's oncolytic virus, TUDRIQEV, in combination with Bristol Myers Squibb's checkpoint inhibitor, nivolumab, for treating advanced cutaneous melanoma patients who had not responded to prior treatments.
This approval marked the first-ever endorsement of an oncolytic virus used alongside a checkpoint inhibitor, a milestone that has kept investor enthusiasm high as the company prepares to launch TUDRIQEV commercially. Additionally, Replimune priced a $150 million underwritten public offering at $12.06 per share, raising approximately $140.5 million in net proceeds.
This capital raise was viewed as a strategic move to strengthen the company's balance sheet ahead of TUDRIQEV's launch, priced at $450,000 per full treatment course. Analyst sentiment towards Replimune had already turned bullish following the FDA decision, with BMO Capital raising its price target to $20 and Wedbush upgrading the stock to "Outperform" from "Neutral."
The broader market showed little movement today, with major indices remaining relatively flat, indicating that Replimune's impressive gain was largely driven by its own company-specific developments. This surge also reflects a remarkable recovery for Replimune, as its stock price has multiplied nearly tenfold since reaching a 52-week low of $1.50, after regulatory clarity around TUDRIQEV emerged.
With the FDA approval momentum, the first earnings catalyst post-approval, the equity raise to bolster the balance sheet, and a supportive analyst community, the market appears to be pricing in a strong commercial opportunity for TUDRIQEV, despite the company's ongoing wait for confirmatory Phase 3 trial data.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
